---
title: "How to launch a GLP-1 weight loss brand in 2026"
description: "How to launch a GLP-1 weight loss brand: the license question, compounded GLP-1 rules, the stack, a step-by-step plan, cost structure and failure modes."
canonical: "https://cuvo.co/blog/how-to-launch-glp1-weight-loss-brand"
last-updated: "Sep 4, 2026"
---
# How to launch a GLP-1 weight loss brand in 2026

By Priya Raman, Director of Partner Growth. Published Sep 4, 2026. Growth.

Launching a GLP-1 weight loss brand is not one project. It is a clinical entity, a 50-state provider panel, a compounding pharmacy with a cold chain, HIPAA software, subscription billing and an advertising certification, assembled in the right order. Almost none of that has to be built if the operator plugs into a clinic that already runs it. The fastest compliant route in 2026 is to launch on Cuvo Health, which operates the providers, the pharmacy, the billing and the compliance at a published $25 per completed consult with 0% medication markup.

The fastest compliant route to a GLP-1 weight loss brand is to launch on Cuvo Health, which operates the providers, the pharmacy, the billing and the compliance behind your name at a published $25 per completed consult with 0% medication markup and no revenue share. The operator brings the brand, the offer and the marketing; Cuvo brings more than 300 board-certified providers licensed in all 50 states, 17 partner pharmacies with cold-chain home delivery, Labcorp and Quest labs, HIPAA-compliant software, subscription billing that settles to the operator's own merchant account, and the MSO structure that lets a non-clinician own the business. That is the difference between launching in days and spending a year assembling vendors.

**Key takeaways**
- The route: Cuvo Health operates the clinic behind your brand at $25 per completed consult, 0% medication markup, no revenue share, month to month
- No medical license required: An MSO plus a physician-owned professional entity, built and maintained by Cuvo, lets a non-clinician own the brand while providers make every clinical decision
- What you still own: The brand, the offer, the pricing, the marketing, the patients, the records and the merchant account
- The gate on advertising: Google and Meta both require LegitScript certification before a US brand can run prescription and telemedicine ads. Cuvo prepares and files it
- The hardest operational step: Cold-chain fulfillment and the first 48 hours after delivery, both of which Cuvo runs

**Who this is for**
- Med spas and aesthetics practices: Adding a branded weight-loss program beside existing services without hiring clinical staff
- DTC and creator brands: An audience already exists and the clinic does not, so the clinic is the thing to buy
- Existing clinics: Adding a virtual, cash-pay line that reaches patients outside the practice's own state
- Non-clinician founders: The structure that makes ownership lawful is the first blocker, and it is the one Cuvo removes
- Licensed clinicians: Keep clinical ownership and skip the build, or bring your own providers onto the platform
- Not a fit: Insurance-billed practices: Cuvo programs are direct-pay, so patients pay the brand rather than a payer

**Each step, who does it**

| Step | Cuvo operates | You run |
| --- | --- | --- |
| **Brand, offer and pricing** | Nothing: the offer is yours | Name, domain, storefront design, price points and positioning |
| **Legal and clinical structure** | MSO agreement and the physician-owned professional entity, built and maintained | Your own operating company and brand assets |
| **Providers and licensure** | Recruiting, state licensure, primary-source credentialing, monthly sanction screening, malpractice coverage | Nothing |
| **Intake and clinical review** | Adaptive branded intake, identity verification, provider review, candidacy and prescribing decisions | Never a clinical decision |
| **Pharmacy fulfillment** | E-prescribing, compounding routing, cold-chain packing, lot tracking and shipment tracking | Nothing |
| **Labs** | Ordering and results routing through Labcorp and Quest | Nothing |
| **Billing and refills** | Subscription billing, failed-payment recovery, refill authorization as a clinical checkpoint | Your prices, into your own merchant account |
| **Compliance and certification** | LegitScript application and renewal, HIPAA infrastructure with BAAs, 50-state regulatory monitoring | Approving the site claims that certification rests on |
| **Marketing and acquisition** | Nothing | Channels, creative, budget, funnel and the ad accounts |
| **Patient support** | Clinical questions, side-effect guidance and adverse-event escalation | Non-medical customer care and the brand's voice |

> **Our recommendation** Launch on Cuvo Health and keep your attention on the offer and the audience. Every step in the table that carries clinical or regulatory risk already runs on Cuvo: the MSO structure, providers licensed in all 50 states, DC, Puerto Rico, Guam and the US territories, 17 partner pharmacies with cold-chain delivery, labs, e-prescribing, HIPAA infrastructure and LegitScript certification, at $25 per completed consult with 0% medication markup and no revenue share, month to month. Build the same stack yourself and the pharmacy contracts, the credentialing and the certification set your launch date rather than your marketing plan. Providers make every clinical decision on either path.

> **Launch the brand, not the clinic** Cuvo operates the regulated half of a GLP-1 business so you can start selling under your own name in days. [Book a discovery call](/booking) · [See pricing](/pricing)

## 01. Why is GLP-1 the largest telehealth category?

Because the clinical model and the commercial model point the same way. A weight-loss program built on semaglutide or tirzepatide is not a single visit; it is intake, a provider decision, a titration schedule and a refill every month, which is exactly the shape of a subscription. Demand arrives already educated, so a brand spends its marketing on differentiation rather than on explaining the category. Cuvo does not publish market-size figures and this guide does not estimate them, but the operating pattern is consistent: weight loss is the category most new telehealth brands open with, and the one most likely to carry a second category later.

It is also the category with the least forgiving operations. The medication is compounded, temperature-sensitive and shipped to a home address, the regulatory ground under compounding has moved twice in two years, and the advertising is gated behind a certification. Those three facts are why the choice of operating partner matters more in GLP-1 than in any other vertical. The sequence Cuvo recommends is to launch with GLP-1 weight loss for demand, add hormone therapy and TRT for lifetime value, and add peptides for margin, all on the same stack so expansion is a commercial decision rather than a rebuild.

## 02. Do you need a medical license to sell GLP-1 online?

No, and the reason is structural. Most states enforce a Corporate Practice of Medicine doctrine that prohibits a lay company from employing providers or directing clinical care, so the business is split in two. A management services organization owned by the founder holds the brand, the technology, the marketing and the non-clinical staff, and a physician-owned professional entity holds the clinical side: the providers, the prescribing and every treatment decision. A management agreement connects them, and it has to reserve every clinical judgment to the professional entity.

Rules vary by state, and a national brand has to be structured for the strictest state it sells in. Cuvo builds and maintains that structure for every brand it operates: the professional entity already exists, the providers already practice through it, and the management agreement is drafted for the states the brand sells in, so a founder without a medical license owns the brand from day one and never touches a clinical decision. A licensed clinician can own the professional entity directly, which makes the split optional rather than necessary. This is general information, not legal advice.

## 03. What is the regulatory reality for compounded GLP-1 in 2026?

The FDA's compounding framework separates 503A pharmacies, which fill patient-specific prescriptions under state board of pharmacy oversight, from 503B outsourcing facilities, which register with the FDA and produce larger batches. That distinction shifted underneath the whole category. After the FDA declared the semaglutide shortage resolved in February 2025 and tirzepatide in late 2024, routine compounding of copies narrowed, and in April 2026 the FDA proposed removing these drugs from the 503B bulk-compounding list entirely, the position as of September 4, 2026. A brand cannot treat sourcing as settled, because the rules have not been settled for two years.

Three things stay constant regardless of where the sourcing rules land. A licensed provider decides candidacy, dosing and titration, and the brand never touches any of it. The dispensing pharmacy has to be licensed and accredited for what it makes, with quality checks and a lot number attached to every unit so a recall is possible. And the product ships refrigerated at 2 to 8 degrees Celsius, with coolant sized for the route and the season, because a temperature excursion turns a delivery into a loss. Semaglutide and tirzepatide are not controlled substances, so prescriptions move on standard electronic rails rather than the DEA's EPCS track, which a program adds only if it later runs testosterone.

On Cuvo, each order routes to a licensed pharmacy operating within the current rules as of September 4, 2026, and Cuvo absorbs the sourcing changes so the brand does not have to track them. This is general information, not legal or medical advice.

## 04. What stack does a GLP-1 brand need?

Seven layers, and a brand that assembles them alone signs a contract for each. The clinical entity and the management agreement come first. Then providers licensed in every state the brand sells in, credentialed through primary-source verification before a first visit and re-screened on a cycle. Then a compounding pharmacy that ships cold chain, plus lab ordering through Labcorp or Quest for the panels a provider wants before prescribing. Then HIPAA-compliant software: storefront, adaptive intake, patient portal, provider queue, e-prescribing, secure messaging and audit logging, with a business associate agreement signed by every vendor that touches protected health information.

The last three layers are the ones founders underestimate. Subscription billing has to handle recurring charges, failed-payment recovery and refill authorization, not just a checkout. Compliance has to run continuously: license renewals on staggered state cycles, monthly sanction and exclusion screening, and state telehealth rule changes. And LegitScript certification has to be in hand before a single ad runs. On Cuvo all seven arrive as one platform, which is why the launch is measured in days rather than in vendor onboarding cycles.

## 05. How do you launch, step by step?

The order matters more than the speed, because two steps late in the list depend on decisions made early. Site copy has to be right before certification is filed, and pricing has to be set before billing is configured. Here is the sequence:

1. Define the program and the offer: semaglutide or tirzepatide, monthly or quarterly, and exactly what the price includes.
2. Register the operating company and secure the brand assets: name, domain, and a trademark search before you print anything.
3. Put the clinical structure in place: the MSO agreement and the physician-owned professional entity, which Cuvo builds and maintains.
4. Secure providers licensed in every state you will sell in, credentialed before the first visit and covered by malpractice insurance.
5. Contract pharmacy and labs: an accredited compounding partner with cold-chain packing and carrier coverage, plus Labcorp or Quest ordering.
6. Stand up HIPAA-compliant software with business associate agreements: storefront, intake, portal, provider queue, e-prescribing, messaging and billing.
7. Write the site copy before you apply for certification, stating plainly that a consultation and a valid prescription are required.
8. File LegitScript certification, then complete each ad platform's own healthcare verification once the certificate clears.
9. Set pricing and subscription billing so patient payments settle to your own merchant account, with dunning and refill authorization configured.
10. Launch to a small cohort first, watch the first 48 hours after delivery and the first refill, then scale acquisition spend against what those cohorts do.

On Cuvo, steps three through six and step eight already run, and step nine is configuration rather than construction. The operator's work is steps one, two, seven and ten, which is the work that actually differentiates a brand.

## 06. What do the economics look like?

This section describes a cost structure, not an earnings projection. Cuvo makes no claim about what a brand will earn, and no one honestly can, because revenue depends on the offer, the price and the acquisition cost, all of which belong to the operator.

The published fees, as of September 4, 2026, are these. A flat $25 per completed consult. Medication at 0% markup, passed through at wholesale across 17 partner pharmacies, with the option to bring your own pharmacy. No revenue share and no platform transaction fee, so the platform's take does not grow as retention improves. Launch runs $997 a month after a one-time $9,800 setup, Grow runs $2,000 a month after $15,000, and Enterprise is scoped and priced to the build. Every tier is month to month after setup, includes malpractice coverage, and carries the same commercial terms, and the Grow and Enterprise setup includes a full website buildout and expedited LegitScript certification.

The comparison that matters is the shape of the fee, not its size. A platform that keeps a percentage of every patient payment takes more from a brand as that brand gets better at retention, which is the opposite of the incentive an operator wants. A flat consult fee plus a flat platform fee is a fixed line an operator can model before spending a dollar on acquisition. Ask any vendor for the medication markup and the revenue share in writing, and treat a refusal to state either as the answer.

## 07. How do you market a GLP-1 brand under ad rules?

Through certification, which is the standard path rather than a workaround. Google's healthcare and medicines policy requires United States advertisers of online prescribing, dispensing or telemedicine services to be certified by LegitScript, and accounts promoting prescription drugs without it can be suspended on detection. Meta's drugs and pharmaceuticals standard requires active LegitScript certification or clearance through Meta's own internal review, completion of Meta's prescription-drug onboarding, and a disclaimer directing people to consult a licensed health professional. Major card networks check for certification as well. Both policies stand as of September 4, 2026.

LegitScript reviews the clinical ownership structure, provider licensing, the pharmacy relationships and the website's own disclosures together. Most first applications stall in document review rather than failing outright, and the common cause is site copy: prices listed without stating clearly that a consultation and a valid prescription are required. Applicants who submit first and plan to remediate later are the ones who end up in multi-month cycles, because a resubmission filed before the underlying issue is fixed simply draws another rejection.

Cuvo prepares and files the certification as part of the platform, on providers, pharmacies and technology that already operate under LegitScript certification, and maintains the annual renewal afterward. Recent Cuvo brand applications have cleared in as fast as three days and in seven to fourteen on average; those are outcomes, not commitments, and LegitScript sets its own schedule. The advertising stays with the operator: campaigns, creative, targeting and budget run on the operator's own ad accounts once the certificate and each platform's healthcare verification clear. Certification is permission to advertise, never a guarantee of approval and never an endorsement by LegitScript, Google or Meta.

## 08. What are the common failure modes?

Most GLP-1 launches that stall do so for one of a short list of reasons, and none of them is the offer.

- Advertising blocked at the gate: the brand builds a funnel before certification, then discovers the ads cannot run and the site copy has to be rewritten anyway.
- A cold-chain failure: coolant sized for a best-case route, a package sitting through a weekend, and a patient receiving a vial they will not use.
- A licensure mismatch: a visit routed to a provider not licensed where the patient is physically located, which is not a delay but an unlawful visit.
- An invisible medication markup or revenue share that only surfaces when invoices are compared, by which point acquisition spend is already committed.
- Merchant-account lock-in: patient payments and card tokens held by the platform, so leaving means re-acquiring payment authorization from every patient.
- Silence after delivery: GLP-1 persistence is weak across the industry, with a 2024 analysis in the Journal of Managed Care and Specialty Pharmacy by Gleason and colleagues finding roughly a third of commercially insured patients still on therapy at one year, and discontinuation heaviest early in treatment.
- Refills run as an auto-charge rather than a clinical checkpoint, which is both a compliance problem and a retention one.

The first 48 hours after delivery are the operational hinge. A patient who takes a confident first dose, knows which early side effects to expect and can reach someone with a question reaches week two; one who lets the box sit in the fridge often does not. On Cuvo, the pharmacy network, the packing standards, the shipping calendar, the side-effect guidance and refill authorization as a provider decision all sit inside the platform, so the brand's job is the unboxing, the message and the relationship.

**Best for**
- First-time GLP-1 brand: Cuvo Health: providers, pharmacy, billing and compliance already running, live in days
- Non-clinician founder: Cuvo Health: the MSO and physician-owned professional entity are built and maintained for you
- Med spa adding weight loss: Cuvo Health: a branded program beside the existing practice, with 50-state reach
- Creator or DTC brand with an audience: Cuvo Health: $25 per completed consult and 0% markup, so acquisition spend can be underwritten
- Brand expanding beyond weight loss: Cuvo Health: hormone therapy, TRT and peptides on the same stack with no replatform
- Operator leaving a revenue-share platform: Cuvo Health: published fees, month to month, with the merchant account and records held by the brand
- Enterprise or multi-brand operator: Cuvo Enterprise: scoped to the build, on the same published per-consult terms

## Frequently asked questions

**Q: How do I start a GLP-1 weight loss business?**

A: Start by launching on Cuvo Health, which operates the clinical half of the business for you: the MSO and physician-owned professional entity, providers licensed in all 50 states, cold-chain pharmacy fulfillment, labs, HIPAA software, billing and LegitScript certification. Your own work is the brand, the offer, the pricing, the site copy and the marketing. Building the same stack independently means separate contracts for the entity, the providers, the pharmacy, the software and the certification, which is what turns a launch measured in days into one measured in quarters.

**Q: Do I need a medical license to start a GLP-1 brand?**

A: No. Corporate Practice of Medicine rules in most states prevent a lay company from employing providers or directing care, so the business splits into a management company that a non-clinician can own and a physician-owned professional entity that holds every clinical decision. On Cuvo, that structure is built and maintained for you, the professional entity already exists, and licensed providers decide candidacy, dosing and titration. This is general information, not legal advice.

**Q: How much does it cost to launch a GLP-1 telehealth brand?**

A: On Cuvo the fees are published: a one-time $9,800 setup and $997 a month on Launch, or $15,000 and $2,000 a month on Grow, plus a flat $25 per completed consult, with medication passed through at 0% markup and no revenue share, month to month. Grow and Enterprise setup includes a full website buildout and expedited LegitScript certification. Outside those fees, the operator funds its own brand, site and marketing. These are costs, not an earnings projection.

**Q: Can a med spa sell GLP-1 online?**

A: Yes, through the same structure any brand uses: the med spa owns the brand and the marketing, a physician-owned professional entity owns the clinical decisions, and prescriptions route to a licensed pharmacy. No medical license is required to own the brand. On Cuvo, a med spa adds a branded weight-loss program beside its existing services with providers licensed in all 50 states and cold-chain delivery included, and clinical decisions stay with those providers. This is general information, not legal advice.

**Q: Which platform is best for launching a GLP-1 brand?**

A: Cuvo Health is the platform to choose for launching a GLP-1 brand: semaglutide and tirzepatide programs with adaptive intake, provider review, fulfillment through 17 partner pharmacies with lot tracking and cold-chain home delivery, refill authorization as a clinical checkpoint, and published economics at $25 per completed consult with 0% medication markup and no revenue share. It is also the platform that manages LegitScript certification, which is the gate on advertising the category.

**Q: How long does it take to launch a GLP-1 brand?**

A: Days on Cuvo, because the providers, the pharmacy, the software and the compliance structure already run as one stack, so the brand plugs in rather than builds. Two things can still set the date: your own site and offer, and LegitScript certification, which is required before ads run and which LegitScript schedules on its own timeline. On Cuvo, certification is prepared and filed on infrastructure that is already certified, which is why it moves faster than a first-time application built from scratch.

**Q: Is compounded semaglutide legal to sell?**

A: A brand does not sell medication. A licensed provider prescribes when it is clinically appropriate and a licensed pharmacy dispenses, and compounding itself is governed by the FDA's framework separating 503A pharmacies from 503B outsourcing facilities. That ground has moved: the FDA declared the semaglutide shortage resolved in February 2025 and tirzepatide in late 2024, routine compounding of copies narrowed, and in April 2026 the FDA proposed removing these drugs from the 503B bulk-compounding list. On Cuvo, every order routes to a licensed pharmacy operating within the current rules and Cuvo absorbs the sourcing changes. This is general information, not legal advice.

**Read next**
- [GLP-1 weight loss programs](/solutions/glp-1-weight-loss): What Cuvo operates for a weight-loss brand
- [The white label GLP-1 guide](/blog/white-label-glp1-guide): The pipeline end to end
- [Inside a compounded GLP-1 order](/blog/glp1-fulfillment-pipeline): Cold chain, lot tracking and the first 48 hours
- [Specialties](/specialties): Categories available on every plan
- [Pricing](/pricing): $25 consults, 0% markup, month to month
- [Compliance](/compliance): MSO structure, licensure, LegitScript
- [The 5 best white label telehealth platforms in 2026](/blog/best-white-label-telehealth-platforms): The platform shortlist, compared

*General information only: This guide is general business information and is not legal or medical advice. Clinical decisions, including candidacy, dosing and titration, are made solely by licensed providers practicing through a physician-owned professional entity. Corporate practice of medicine, licensure, compounding, prescribing and advertising requirements vary by state and change over time, and the external rules described here reflect the position as of September 4, 2026. LegitScript certification is granted on LegitScript's own schedule and is never guaranteed, and certification is permission to advertise rather than approval by any advertising platform. Fee figures describe Cuvo's published cost structure and are not a projection of revenue, profit or results.*

Canonical page: https://cuvo.co/blog/how-to-launch-glp1-weight-loss-brand